Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 9 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 9 of 10.)

DateHeadlineEventSource5-minTo close
Form 10-Q JOHNSON & JOHNSON For: Jun 30SEC filing · Form 10-QSEC EDGAR+0.47%+0.56%
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferencePress releaseBusiness Wire-0.07%+2.30%
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionPress releasePR Newswire+0.05%-0.34%
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanPress releaseBusiness Wire-0.10%-0.01%
Form 8-K JOHNSON & JOHNSON For: Jul 17SEC filing · Form 8-KSEC EDGAR+1.74%+3.31%
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024Press releaseBusiness Wire+1.74%+3.31%
Johnson & Johnson reports Q2 2024 resultsPress releaseBusiness Wire+1.74%+3.31%
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26Press releaseBusiness Wire-0.52%+0.08%
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsPress releaseCanada Newswire-0.45%-0.35%
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyPress releasePR Newswire+0.29%-0.29%
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsPress releasePR Newswire+0.06%-0.32%
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurduePress releaseBusiness Wire+0.26%+0.08%
Form 11-K/A JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.09%+0.42%
Form 11-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR-0.10%-1.25%
Johnson & Johnson Completes Acquisition of Proteologix, Inc.Press releaseBusiness Wire+0.04%+0.58%
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseasePress releasePR Newswire+0.04%+0.58%
More than 60 Law Firms Oppose J&J Prepack Bankruptcy SchemePress releaseBusiness Wire-0.13%+0.18%
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous inductionPress releasePR Newswire+0.23%+1.83%
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc ProductsPress releaseBusiness Wire+0.04%-0.10%
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.78%+0.64%
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 studyPress releasePR Newswire+0.78%+0.64%
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myelomaPress releasePR Newswire+0.34%+0.28%
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy StrategyPress releaseBusiness Wire+0.04%-0.01%
DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty ProceduresPress releasePR Newswire-0.07%+0.27%
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsPress releaseBusiness Wire-0.39%-1.36%
Johnson & Johnson Completes Acquisition of Shockwave MedicalPress releaseBusiness Wire+0.26%+0.76%
Form SD JOHNSON & JOHNSONSEC filing · Form SDSEC EDGAR+0.89%+0.40%
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic DermatitisPress releaseBusiness Wire-0.72%-1.64%
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic DermatitisPress releaseGlobeNewswire-0.72%-1.64%
Form CERT JOHNSON & JOHNSONSEC filing · Form CERTSEC EDGAR-0.13%-0.17%
Form 8-A12B JOHNSON & JOHNSONSEC filing · Form 8-A12BSEC EDGAR-0.01%-0.36%
Form 8-K JOHNSON & JOHNSON For: May 20SEC filing · Form 8-KSEC EDGAR-0.01%-0.36%
Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual MeetingPress releasePR Newswire-0.57%-1.20%
Form 8-K JOHNSON & JOHNSON For: May 17SEC filing · Form 8-KSEC EDGAR-0.12%+0.27%
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis TreatmentPress releaseBusiness Wire-0.31%+0.84%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR-0.19%+0.79%
Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping SystemPress releasePR Newswire+0.16%-0.11%
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferencePress releaseBusiness Wire+0.03%+0.58%
Form 10-Q JOHNSON & JOHNSON For: Mar 31SEC filing · Form 10-QSEC EDGAR-0.62%+1.62%
Form 8-K JOHNSON & JOHNSON For: May 01SEC filing · Form 8-KSEC EDGAR-0.62%+1.62%
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” ReorganizationPress releaseBusiness Wire-0.62%+1.62%
Form 8-K JOHNSON & JOHNSON For: Apr 25SEC filing · Form 8-KSEC EDGAR-0.59%-1.56%
Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness MonthPress releasePR Web-0.24%+0.59%
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)Press releaseBusiness Wire-0.27%-0.03%
Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson & Johnson, Kenvue, Inc.Press releaseBusiness Wire-0.27%+0.41%
Form 8-K JOHNSON & JOHNSON For: Apr 16SEC filing · Form 8-KSEC EDGAR+1.19%+0.31%
Form 8-K/A JOHNSON & JOHNSON For: Apr 16SEC filing · Form 8-KSEC EDGAR-0.11%-0.25%
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%Press releaseBusiness Wire+1.19%+0.31%
Johnson & Johnson Reports Q1 2024 ResultsPress releaseBusiness Wire+1.19%+0.31%
Signature Resolution Welcomes Hon. Eddie C. Sturgeon (Ret.) to Panel of NeutralsPress releasePR Web-0.13%-0.65%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground